Evidence map›Paper›PMID 40281084›Full record

ArticleScientific reports2025

Evaluation of serum calprotectin levels in patients with polycystic ovary syndrome.

Rıfat Şener, Süleyman Erkan Alataş, Ömer Tolga Güler

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rıfat ŞenerDepartment of Gynecology and Obstetrics, Gynecological Oncology Surgery, Konya City Hospital, Konya, Turkey. rifatsener190@gmail.com.ORCID http://orcid.org/0000-0002-7297-5486
Süleyman Erkan AlataşDepartment of Gynecology and Obstetrics, Faculty of Medicine, Pamukkale University, Denizli, Turkey.ORCID http://orcid.org/0000-0001-6423-5106
Ömer Tolga GülerDepartment of Gynecology and Obstetrics, Faculty of Medicine, Pamukkale University, Denizli, Turkey.ORCID http://orcid.org/0000-0001-6673-8604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. PCOS is associated with many chronic complications such as endometrial thickening, endometrial cancer, breast cancer, infertility, dyslipidemia, and long-term cardiovascular disease. Therefore, many parameters and markers should be used in the evaluation of patients diagnosed with PCOS. Calprotectin has also been shown to be an important marker of destruction in many diseases that progress with inflammatory processes. The objective of our study was to examine the diagnostic efficacy of calprotectin in the context of polycystic ovary syndrome. In this study, 39 patients diagnosed with polycystic ovary syndrome and 41 healthy controls were analyzed. Serum calprotectin levels were compared between patients with different phenotypes of PCOS and a control group. Our study demonstrates significant differences in hormonal and inflammatory parameters between PCOS patients and healthy controls. PCOS patients exhibited significantly lower FSH levels and higher LH levels, resulting in a marked increase in the LH/FSH ratio. Additionally, DHEA-S and total testosterone levels were significantly elevated in the PCOS group, while SHBG levels were notably lower. The free androgen index (FAI) and serum calprotectin levels were also significantly higher in the PCOS group, highlighting the potential role of calprotectin in the pathophysiology of the disorder. Our study demonstrated that serum calprotectin levels are significantly higher in patients with PCOS compared to healthy controls. This finding underscores the potential role of calprotectin in the pathophysiology of PCOS and suggests that this marker could provide valuable insights into the inflammatory processes associated with the condition. However, further large-scale and long-term studies are necessary to better understand the impact of calprotectin on different PCOS phenotypes and its potential application in clinical practice.

Indexed as

Leukocyte L1 Antigen ComplexPolycystic Ovary SyndromeAdultBiomarkersCase-Control StudiesFemaleFollicle Stimulating HormoneHumansLuteinizing HormoneSex Hormone-Binding GlobulinTestosteroneYoung AdultBiomarkersFollicle Stimulating HormoneLeukocyte L1 Antigen ComplexLuteinizing HormoneSex Hormone-Binding GlobulinTestosteroneCalprotectinPhenotypePolicystic ovary syndrome

Identifiers

PMID40281084
PMCPMC12032230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.